5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
How Endocyte (ECYT) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:36AM CDT
Endocyte is seeing solid earnings estimate revision activity and also has a great company from a Zacks Industry Rank perspective
Endocyte (ECYT) Showing Signs Of A Dead Cat Bounce Today
at The Street - Mon Apr 07, 9:25AM CDT
Trade-Ideas LLC identified Endocyte (ECYT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Product Launches, Acquisitions, Closed Offerings, Divestitures, and Financial Results - Analyst Notes on Dr. Reddy's, ICON, Endocyte, BioScrip, and DepoMed
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Endocyte Announces Presentations at AACR Annual Meeting 2014
GlobeNewswire - Fri Apr 04, 7:17AM CDT
Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that three posters will be presented by Endocyte scientists at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, April 5-9, 2014.
Can Endocyte (ECYT) Run Higher on Strong Earnings Estimate Revisions? (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 12:06PM CDT
Not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Can Endocyte (ECYT) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 7:47AM CDT
Endocyte, a biopharmaceutical company, could be a solid choice for investors, as it has witnessed solid activity on the earnings estimate revision front and the company also has a favorable Zacks Rank.
Endocyte, Inc. Closes Public Offering of Common Stock
GlobeNewswire - Wed Apr 02, 3:01PM CDT
Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase 675,000 additional shares. Endocyte received net proceeds of approximately $101.8 million from the offering after deducting underwriting discounts and commissions and estimated expenses relating to the offering.
'Mad Money' Lightning Round: Don't Buy eBay
at The Street - Tue Apr 01, 5:00AM CDT
Cramer says he's disappointed by Volaris, missed on Endocyte but likes GNC Holdings and Chicago Mercantile Exchange.
Jim Cramer's 'Mad Money' Recap: Out With a Bang
at The Street - Mon Mar 31, 7:01PM CDT
Cramer says the only thing shocking about Michael Lewis' new book on high-frequency trading is that people find it shocking at all.
Big Pharma Failure = Biotech Takeover?
David Williamson, The Motley Fool - Motley Fool - Mon Mar 31, 5:33PM CDT
Today's big winner in biotech was Endocyte , up 7% on a case of schadenfreude. Its potential big pharma competitor GlaxoSmithKline decided to withdraw an expanded indication of its kidney cancer drug Votrient into ovarian cancer, because of...
Endocyte Prices New Offering at $21 Per Share - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:30PM CDT
Endocyte shares fell 4.8% following the announcement of its intention to issue shares and the pricing of the underwritten public offering of its common stock.
Endocyte (ECYT) Slips After Pricing Share Offering
at The Street - Fri Mar 28, 1:04PM CDT
Endocyte (ECYT) is sliding on Friday after pricing its previously-announced share offering.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Overall Survival Will Be Critical for Endocyte's Vintafolide
Catherine Shaffer, The Motley Fool - Motley Fool - Fri Mar 28, 8:00AM CDT
Shares of Endocyte nearly doubled overnight when it announced positive results from a Phase IIb trial of vintafolide and docetaxel in non-small cell lung cancer (NSCLC). At the same time, the company reported that Europe's Committee for Medicinal...
Endocyte (ECYT) in Focus: Stock Tumbles 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 7:47AM CDT
Endocyte, Inc. (ECYT) saw a big move last session, reversing the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.
Endocyte, Inc. Prices Public Offering of Common Stock
GlobeNewswire - Thu Mar 27, 5:49PM CDT
Endocyte, Inc. (Nasdaq:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Endocyte, will be approximately $94.5 million. Endocyte has also granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. The offering is expected to close on or about April 2, 2014, subject to customary closing conditions. Endocyte anticipates using the net proceeds from the offering for working capital and general corporate purposes, including without limitation research and development expenses, including clinical trial costs, capital expenditures and general and administrative expenses.
Will Vintafolide Approval Silence Endocyte Bears?
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 1:38PM CDT
Unless you've been asleep for a week, you probably noticed that Endocyte shot up over 150% last Friday, before settling near a 100% gain. Nearly two years ago Merck made a deal with Endocyte potentially worth $1 billion. The uncommonly big deal...
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?